Loading...

We've got a brand new version of Simply Wall St! Try it out

Innovotech

TSXV:IOT
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IOT
TSXV
CA$2M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Innovotech Inc. provides services and solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada and internationally. The last earnings update was 92 days ago. More info.


Add to Portfolio Compare Print
  • Innovotech has significant price volatility in the past 3 months.
IOT Share Price and Events
7 Day Returns
0%
TSXV:IOT
-0.5%
North America Life Sciences
-1.4%
CA Market
1 Year Returns
-8.3%
TSXV:IOT
10.4%
North America Life Sciences
-4.4%
CA Market
IOT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Innovotech (IOT) 0% -8.3% 10% -8.3% 266.7% 37.5%
North America Life Sciences -0.5% -4% 3.3% 10.4% 68.7% 100.2%
CA Market -1.4% -2.7% -3.1% -4.4% 3.4% -3.3%
1 Year Return vs Industry and Market
  • IOT underperformed the Life Sciences industry which returned 10.4% over the past year.
  • IOT underperformed the Market in Canada which returned -4.4% over the past year.
Price Volatility
IOT
Industry
5yr Volatility vs Market

IOT Value

 Is Innovotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Innovotech. This is due to cash flow or dividend data being unavailable. The share price is CA$0.055.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Innovotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Innovotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:IOT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$0.00
TSXV:IOT Share Price ** TSXV (2019-08-16) in CAD CA$0.06
North America Life Sciences Industry PE Ratio Median Figure of 21 Publicly-Listed Life Sciences Companies 34.35x
Canada Market PE Ratio Median Figure of 532 Publicly-Listed Companies 13.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Innovotech.

TSXV:IOT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:IOT Share Price ÷ EPS (both in CAD)

= 0.06 ÷ 0.00

-30.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innovotech is loss making, we can't compare its value to the North America Life Sciences industry average.
  • Innovotech is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Innovotech's expected growth come at a high price?
Raw Data
TSXV:IOT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -30.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 2.74x
Canada Market PEG Ratio Median Figure of 249 Publicly-Listed Companies 0.9x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Innovotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Innovotech's assets?
Raw Data
TSXV:IOT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.00
TSXV:IOT Share Price * TSXV (2019-08-16) in CAD CA$0.06
North America Life Sciences Industry PB Ratio Median Figure of 41 Publicly-Listed Life Sciences Companies 4.67x
Canada Market PB Ratio Median Figure of 2,453 Publicly-Listed Companies 1.42x
TSXV:IOT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:IOT Share Price ÷ Book Value per Share (both in CAD)

= 0.06 ÷ 0.00

24.69x

* Primary Listing of Innovotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innovotech is overvalued based on assets compared to the North America Life Sciences industry average.
X
Value checks
We assess Innovotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Innovotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IOT Future Performance

 How is Innovotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.3%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Innovotech expected to grow at an attractive rate?
  • Unable to compare Innovotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Innovotech's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Innovotech's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:IOT Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.3%
North America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:IOT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:IOT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 0 0
2018-12-31 1 0 0
2018-09-30 1 0 0
2018-06-30 1 0 1
2018-03-31 1 0 1
2017-12-31 1 0 1
2017-09-30 1 0 1
2017-06-30 1 0 0
2017-03-31 1 0 0
2016-12-31 1 0 0
2016-09-30 1 0 0
2016-06-30 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Innovotech is high growth as no earnings estimate data is available.
  • Unable to determine if Innovotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:IOT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Innovotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:IOT Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.02
2018-03-31 0.02
2017-12-31 0.02
2017-09-30 0.02
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 -0.01
2016-09-30 0.00
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Innovotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of IOT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Innovotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Innovotech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Innovotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Innovotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IOT Past Performance

  How has Innovotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Innovotech's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Innovotech does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Innovotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Innovotech's 1-year growth to the North America Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Innovotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Innovotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:IOT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.83 -0.07 0.65 0.02
2018-12-31 0.83 -0.13 0.70 0.04
2018-09-30 0.82 -0.13 0.64 0.11
2018-06-30 0.86 0.57 0.66 0.09
2018-03-31 0.88 0.61 0.66 0.07
2017-12-31 0.99 0.75 0.61 0.06
2017-09-30 1.14 0.59 0.69 0.00
2017-06-30 1.14 -0.06 0.62 0.00
2017-03-31 1.13 -0.10 0.55 0.09
2016-12-31 1.01 -0.22 0.50 0.13
2016-09-30 0.83 -0.13 0.44 0.18
2016-06-30 0.75 -0.21 0.42 0.22
2016-03-31 0.73 -0.24 0.45 0.18
2015-12-31 0.71 -0.25 0.45 0.16
2015-09-30 0.92 -0.04 0.45 0.13
2015-06-30 0.87 -0.12 0.47 0.14
2015-03-31 0.88 -0.14 0.49 0.15
2014-12-31 0.90 -0.21 0.54 0.17
2014-09-30 0.71 -0.65 0.77 0.19
2014-06-30 0.75 -0.72 0.84 0.20
2014-03-31 0.93 -0.60 0.96 0.09
2013-12-31 0.89 -0.83 1.05 0.21
2013-09-30 0.94 -0.97 0.99 0.42
2013-06-30 1.10 -1.00 1.07 0.48
2013-03-31 0.86 -1.46 1.11 0.70
2012-12-31 0.87 -1.50 1.22 0.62
2012-09-30 0.91 -1.41 1.16 0.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Innovotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Innovotech has efficiently used its assets last year compared to the North America Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Innovotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Innovotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Innovotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IOT Health

 How is Innovotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Innovotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Innovotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Innovotech has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Innovotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Innovotech Company Filings, last reported 4 months ago.

TSXV:IOT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 0.08 0.10 0.02
2018-12-31 0.09 0.10 0.03
2018-09-30 0.06 0.02 0.04
2018-06-30 0.07 0.00 0.07
2018-03-31 0.14 0.00 0.12
2017-12-31 0.18 0.11 0.32
2017-09-30 -0.10 0.07 0.09
2017-06-30 -0.78 0.08 0.37
2017-03-31 -1.15 0.10 0.07
2016-12-31 -1.22 0.13 0.03
2016-09-30 -1.08 0.14 0.02
2016-06-30 -1.12 0.14 0.02
2016-03-31 -1.05 0.11 0.01
2015-12-31 -1.00 0.11 0.03
2015-09-30 -0.95 0.11 0.01
2015-06-30 -0.91 0.11 0.03
2015-03-31 -0.83 0.11 0.07
2014-12-31 -0.77 0.11 0.00
2014-09-30 -0.93 0.11 0.02
2014-06-30 -0.80 0.11 0.07
2014-03-31 -0.69 0.05 0.04
2013-12-31 -0.57 0.05 0.04
2013-09-30 -0.31 0.00 0.06
2013-06-30 -0.11 0.00 0.04
2013-03-31 -0.16 0.00 0.16
2012-12-31 0.03 0.00 0.45
2012-09-30 0.19 0.00 0.24
  • Innovotech's level of debt (123.8%) compared to net worth is high (greater than 40%).
  • Innovotech had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Innovotech has less than a year of cash runway based on current free cash flow.
  • Innovotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 79% each year.
X
Financial health checks
We assess Innovotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Innovotech has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IOT Dividends

 What is Innovotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Innovotech dividends.
If you bought CA$2,000 of Innovotech shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Innovotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Innovotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:IOT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.7%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Innovotech has not reported any payouts.
  • Unable to verify if Innovotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Innovotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Innovotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Innovotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Innovotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Innovotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IOT Management

 What is the CEO of Innovotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Timourian
COMPENSATION CA$18,000
CEO Bio

Dr. James Timourian, Ph.D. has been the President of Innovotech Inc. since January 01, 2014 and serves as its Chief Executive Officer and Secretary. Dr. Timourian has been Mathematician President of Integral Chemistry Inc. since January 1998. He served as Chief Financial Officer at Innovotech Inc until January 01, 2014. He served as Professor of Mathematics at University of Alberta until 2000. Dr. Timourian has been the Chairman of Innovotech Inc. since August 27, 2013 and its Director since October 22, 2002.

CEO Compensation
  • Insufficient data for James to compare compensation growth.
  • James's remuneration is lower than average for companies of similar size in Canada.
Management Team

James Timourian

TITLE
Chairman
COMPENSATION
CA$18K

Alan Savage

TITLE
CFO & Director
AGE
76
TENURE
1.6 yrs

Amin Omar

TITLE
Chief Operating Officer
COMPENSATION
CA$122K

Merle Olson

TITLE
Scientific Consultant
Board of Directors Tenure

Average tenure of the Innovotech board of directors in years:

4.1
Average Tenure
  • The tenure for the Innovotech board of directors is about average.
Board of Directors

James Timourian

TITLE
Chairman
COMPENSATION
CA$18K
TENURE
6 yrs

Alan Savage

TITLE
CFO & Director
AGE
76
TENURE
2.3 yrs

Gerard Tertzakian

TITLE
Independent Director
TENURE
18.6 yrs

Bernard Grobbelaar

TITLE
Director
COMPENSATION
CA$38K
TENURE
6.3 yrs

David Tam

TITLE
Director
TENURE
1 yrs

Craig Milne

TITLE
Director
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Innovotech individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
31. Jul 19 Buy Alan Savage Individual 29. Jul 19 31. Jul 19 128,000 CA$0.07 CA$8,699
23. Jul 19 Buy Alan Savage Individual 22. Jul 19 22. Jul 19 2,000 CA$0.05 CA$100
21. Jun 19 Buy Alan Savage Individual 21. Jun 19 21. Jun 19 7,000 CA$0.06 CA$420
13. Jun 19 Buy Alan Savage Individual 13. Jun 19 13. Jun 19 5,000 CA$0.07 CA$350
11. Jun 19 Buy Alan Savage Individual 11. Jun 19 11. Jun 19 30,000 CA$0.07 CA$1,930
05. Jun 19 Buy Alan Savage Individual 05. Jun 19 05. Jun 19 2,000 CA$0.06 CA$120
04. Jun 19 Buy Alan Savage Individual 04. Jun 19 04. Jun 19 5,000 CA$0.07 CA$350
30. May 19 Buy Alan Savage Individual 27. May 19 30. May 19 55,000 CA$0.08 CA$3,716
28. May 19 Buy Alan Savage Individual 28. May 19 28. May 19 5,000 CA$0.07 CA$350
27. May 19 Buy Alan Savage Individual 24. May 19 27. May 19 108,000 CA$0.06 CA$6,329
24. May 19 Buy Alan Savage Individual 23. May 19 24. May 19 30,000 CA$0.06 CA$1,869
22. May 19 Buy Alan Savage Individual 22. May 19 22. May 19 67,000 CA$0.06 CA$3,820
01. May 19 Buy Alan Savage Individual 01. May 19 01. May 19 6,000 CA$0.05 CA$330
30. Apr 19 Buy Alan Savage Individual 29. Apr 19 29. Apr 19 12,000 CA$0.06 CA$720
15. Feb 19 Buy David Tam Individual 14. Feb 19 14. Feb 19 100,000 CA$0.05 CA$5,000
13. Feb 19 Buy Alan Savage Individual 13. Feb 19 13. Feb 19 7,000 CA$0.06 CA$420
08. Feb 19 Buy Alan Savage Individual 08. Feb 19 08. Feb 19 6,000 CA$0.07 CA$420
07. Feb 19 Buy Alan Savage Individual 07. Feb 19 07. Feb 19 15,000 CA$0.07 CA$1,050
06. Feb 19 Buy Alan Savage Individual 06. Feb 19 06. Feb 19 1,000 CA$0.06 CA$60
19. Jan 19 Buy David Tam Individual 17. Jan 19 17. Jan 19 100,000 CA$0.05 CA$5,000
18. Jan 19 Buy Alan Savage Individual 18. Jan 19 18. Jan 19 38,000 CA$0.05 CA$1,900
10. Jan 19 Buy Alan Savage Individual 10. Jan 19 10. Jan 19 100,000 CA$0.05 CA$5,000
09. Jan 19 Buy Alan Savage Individual 09. Jan 19 09. Jan 19 200,000 CA$0.05 CA$10,000
14. Dec 18 Buy David Tam Individual 11. Dec 18 11. Dec 18 300,000 CA$0.05 CA$15,000
07. Dec 18 Buy Alan Savage Individual 07. Dec 18 07. Dec 18 125,000 CA$0.05 CA$6,250
06. Dec 18 Buy Alan Savage Individual 06. Dec 18 06. Dec 18 14,000 CA$0.05 CA$700
05. Dec 18 Buy Alan Savage Individual 05. Dec 18 05. Dec 18 5,000 CA$0.05 CA$250
04. Dec 18 Buy Alan Savage Individual 04. Dec 18 04. Dec 18 100,000 CA$0.05 CA$5,000
30. Nov 18 Buy Alan Savage Individual 30. Nov 18 30. Nov 18 100,000 CA$0.05 CA$5,500
21. Nov 18 Buy Alan Savage Individual 20. Nov 18 20. Nov 18 100,000 CA$0.06 CA$5,500
19. Nov 18 Buy Alan Savage Individual 19. Nov 18 19. Nov 18 100,000 CA$0.06 CA$5,500
18. Nov 18 Buy Alan Savage Individual 16. Nov 18 16. Nov 18 70,000 CA$0.05 CA$3,500
15. Nov 18 Buy Alan Savage Individual 15. Nov 18 15. Nov 18 100,000 CA$0.05 CA$5,000
14. Nov 18 Buy Alan Savage Individual 14. Nov 18 14. Nov 18 200,000 CA$0.05 CA$10,000
25. Sep 18 Buy Alan Savage Individual 25. Sep 18 25. Sep 18 23,000 CA$0.05 CA$1,150
20. Sep 18 Buy Alan Savage Individual 17. Sep 18 17. Sep 18 27,000 CA$0.05 CA$1,350
X
Management checks
We assess Innovotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Innovotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IOT News

Simply Wall St News

Is Innovotech's (CVE:IOT) 267% Share Price Increase Well Justified?

See our latest analysis for Innovotech With just CA$833,160 worth of revenue in twelve months, we don't think the market considers Innovotech to have proven its business plan. … Investors will be hoping that Innovotech can make progress and gain better traction for the business, before it runs low on cash. … A Different Perspective Innovotech shareholders are down 8.3% for the year, but the market itself is up 0.8%.

Simply Wall St -

How Does Investing In Innovotech Inc. (CVE:IOT) Impact The Volatility Of Your Portfolio?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one. … Companies with market capitalisations around this size often show poor correlation with the broader market because market volatility is overshadowed by company specific events, or other factors.

Simply Wall St -

What Kind Of Shareholder Appears On The Innovotech Inc.'s (CVE:IOT) Shareholder Register?

Innovotech is a smaller company with a market capitalization of CA$2.4m, so it may still be flying under the radar of many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that institutional investors have not yet purchased shares. … Insider Ownership Of Innovotech The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

What Does Innovotech Inc.'s (CVE:IOT) Balance Sheet Tell Us About It?

(CVE:IOT) is a small-cap stock with a market capitalization of CA$2.0m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health.

Simply Wall St -

What Percentage Of Innovotech Inc. (CVE:IOT) Shares Do Insiders Own?

A look at the shareholders of Innovotech Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Innovotech is not a large company by global standards.

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For Innovotech Inc. (CVE:IOT)?

Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

What Investors Should Know About Innovotech Inc's (CVE:IOT) Financial Strength

Investors are always looking for growth in small-cap stocks like Innovotech Inc (CVE:IOT), with a market cap of CA$2.4m. … However, an important fact which most ignore is: how financially healthy is the business? … especially ones that are currently loss-making,

Simply Wall St -

Is It Time To Buy Innovotech Inc (CVE:IOT) Based Off Its PE Ratio?

I am writing today to help inform people who are new to the stock market. … and want to begin learning the link between Innovotech Inc (CVE:IOT)’s fundamentals and stock market performance. … Innovotech Inc (CVE:IOT) is currently trading at a trailing P/E of 3.9x, which is lower than the industry average of 39.4x.

Simply Wall St -

IOT Company Info

Description

Innovotech Inc. provides services and solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada and internationally. The company’s products include InnovoSIL, the antimicrobial agents for coating onto or incorporation into medical devices; MBEC Assay, a screening assay used to determine the efficacy of antimicrobials against biofilms of various microorganisms; and Agress/AgreGuard, an environmentally friendly seed treatments and plant sprays to protect crops against both bacterial and fungal infections. Its products also include MBEC Assay's biofilm inoculator comprising plastic lids with 96 pegs to simulate the surface conditions on which microorganisms attach and grow. The company’s services cover implant medical devices, bacteriophage and cytotoxicity testing, and in vitro antimicrobial testing, as well as antibiotic, antimicrobial, and biocide resistance. It serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food safety, transportation, and healthcare. The company is headquartered in Edmonton, Canada.

Details
Name: Innovotech Inc.
IOT
Exchange: TSXV
Founded:
CA$1,993,178
36,239,612
Website: http://www.innovotech.ca
Address: Innovotech Inc.
2011-94 Street,
Suite 101,
Edmonton,
Alberta, T6N 1H1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV IOT Class A Common Shares TSX Venture Exchange CA CAD 06. Jul 2004
Number of employees
Current staff
Staff numbers
0
Innovotech employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/17 23:53
End of day share price update: 2019/08/16 00:00
Last earnings filing: 2019/05/17
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.